List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 804 studies with search of: Open Studies | "Stem Cell Transplantation"
Include studies that are not seeking new volunteers.
Hide studies with unknown recruitment status.
  Display Options
Rank Status Study
1 Recruiting The Clinical Trial Research of Stem Cell Transplantation Treats Cerebral
Condition: Stroke
Intervention: Procedure: stem cell transplantation
2 Recruiting Autologous Stem Cell Transplant Followed By Donor Stem Cell Transplant In Treating Patients With Relapsed or Refractory Lymphoma
Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Burkitt Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Prolymphocytic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Splenic Marginal Zone Lymphoma;   Waldenstrom Macroglobulinemia
Interventions: Procedure: peripheral blood stem cell transplantation;   Drug: cyclophosphamide;   Radiation: total-body irradiation;   Drug: carmustine;   Drug: etoposide;   Drug: cytarabine;   Drug: melphalan;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Drug: cyclosporine;   Procedure: autologous hematopoietic stem cell transplantation;   Biological: therapeutic autologous lymphocytes
3 Recruiting Difference Between Rehabilitation Therapy and Stem Cells Transplantation in Patients With Spinal Cord Injury in China
Condition: Spinal Cord Injuries
Interventions: Procedure: rehabilitation of limb function;   Procedure: Stem Cells Transplantation
4 Recruiting Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors
Condition: Hematologic Neoplasms
Interventions: Drug: Cyclophosphamide;   Other: Hematopoietic Stem Cell Transplantation,
5 Recruiting Safety and Efficacy of Stem Cell Transplantation for Treatment of Liver Cirrhosis
Condition: Other Surgical Procedures
Intervention: Procedure: stem cell transplantation through interventional procedures
6 Recruiting 5-azacytidine Treatment Versus 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Myelodysplastic Syndrome (MDS)
Conditions: Myelodysplastic Syndrome;   Chronic Myelomonocytic Leukemia
Interventions: Procedure: allogeneic stem cell transplantation;   Procedure: 5-azacytidine until progress
7 Recruiting Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Lenalidomide;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Rituximab;   Drug: Thymoglobulin;   Procedure: Stem Cell Transplantation;   Drug: Bendamustine;   Drug: Allopurinol
8 Recruiting Safety and Efficacy Study of Autologous Stem Cell Transplantation for Early Onset Type I Diabetes Mellitus
Condition: Type 1 Diabetes Mellitus
Interventions: Procedure: Immunosuppression and autologous stem cell transplantation;   Procedure: Autologous hematopoietic stem cell transplantation
9 Recruiting Sequential Myeloablative Autologous Stem Cell Transplantation Followed by Allogeneic Non-Myeloablative Stem Cell Transplantation for Patients With Poor Risk Lymphomas
Conditions: Diffuse, Large B-Cell, Lymphoma;   Lymphoma, Low-Grade;   T-Cell Lymphoma;   Mantle-Cell Lymphoma;   Hodgkin's Lymphoma;   Chronic Lymphocytic Leukemia;   Lymphoma, Small Lymphocytic
Interventions: Drug: Busulfan;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Phenytoin;   Drug: Ursodiol;   Other: Infusion of autologous peripheral blood stem cells;   Drug: Neupogen;   Drug: Fludarabine;   Other: Peripheral blood stem cell transplant;   Drug: Tacrolimus;   Drug: Sirolimus;   Drug: Methotrexate
10 Recruiting Efficacy and Safety Study of Autologous Hematopoietic Stem Cell Transplantation to Treat New Onset Type 1 Diabetes
Condition: Type 1 Diabetes
Intervention: Procedure: immunosuppression and stem cell transplantation
11 Recruiting 90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Procedure: peripheral blood stem cell transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Procedure: allogeneic hematopoietic stem cell transplantation;   Radiation: yttrium Y 90 anti-CD45 monoclonal antibody BC8
12 Recruiting Autologous Peripheral Blood Stem Cell Transplantation With In Vivo Purging as an Alternate Stem Cell Transplantation Program for Pts w/AML in 1st & 2nd Complete Remission w/no HLA Matched Related Donor
Condition: Leukemia, Monocytic, Acute
Intervention: Drug: Autologous peripheral Bld Stem Cell Transplantation with In Vivo Purging as an alternate stem cell transplantation
13 Recruiting Haematopoietic Stem Cell Transplantation (HSCT) in Comparison to Conventional Consolidation Therapy for Patients With Acute Myeloid Leukemia (AML) (Intermediate Risk) <= 60y. After First CR
Condition: Leukemia, Myeloid, Acute
Interventions: Biological: Human Stem Cell Transplantation;   Drug: Consolidation chemotherapy, i.e. High-dose Cytarabine (HiDAC)
14 Recruiting Study of Allogeneic Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease
Condition: Sickle Cell Disease
Interventions: Procedure: Allogeneic Non-Myeloablative Stem Cell Transplantation;   Drug: Alemtuzumab;   Drug: Sirolimus
15 Recruiting Allogeneic Genoidentical Stem Cell Transplantation in Children With Sickle-cell Anemia and Cerebral Vasculopathy
Conditions: Sickle Cell Anemia;   Cerebrovascular Accident
Interventions: Procedure: Stem cell transplantation;   Procedure: Transfusion program
16 Recruiting Yttrium Y 90 Ibritumomab Tiuxetan With or Without Rituximab, Combination Chemotherapy, and an Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
Condition: Lymphoma
Interventions: Biological: rituximab;   Drug: carmustine;   Drug: cytarabine;   Drug: etoposide;   Drug: melphalan;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: yttrium Y 90 ibritumomab tiuxetan
17 Not yet recruiting Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
Conditions: Leukemia;   Lymphoma
Interventions: Drug: Rituximab;   Drug: 111In Ibritumumab;   Procedure: Planar Scintigraphy Imaging;   Drug: 90Y IbritumumabTiuxetan;   Drug: Fludarabine;   Drug: Bendamustine;   Drug: Thymoglobulin;   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: Mycophenolate;   Drug: G-CSF;   Procedure: Stem Cell Transplantation
18 Recruiting Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, Indium In-111 Ibritumomab Tiuxetan, Fludarabine, Melphalan, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin Lymphoma
Conditions: Graft Versus Host Disease;   Leukemia;   Lymphoma
Interventions: Biological: rituximab;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: sirolimus;   Drug: tacrolimus;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Radiation: indium In 111 ibritumomab tiuxetan;   Radiation: yttrium Y 90 ibritumomab tiuxetan
19 Recruiting Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma
Condition: Lymphoma
Interventions: Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: gemcitabine hydrochloride;   Drug: ifosfamide;   Drug: mechlorethamine hydrochloride;   Drug: melphalan;   Drug: methotrexate;   Drug: mycophenolate mofetil;   Drug: prednisone;   Drug: procarbazine hydrochloride;   Drug: vincristine sulfate;   Drug: vinorelbine tartrate;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
20 Not yet recruiting A New Method to Treat Hereditary Cerebellar Ataxia - Umbilical Cord Mesenchymal Stem Cells Transplantation
Condition: Hereditary Cerebellar Ataxia.
Intervention: Other: stem cell transplantation

Previous Page Studies Shown (1-20) Next Page (21-40)
† Indicates status has not been verified in more than two years
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services